Recruiting

Observational Study

Sponsor:

Mayo Clinic

Code:

NCT07604220

Conditions

Cardiac Sarcoidosis

Sarcoidosis of the Heart

Sarcoidosis With Myocarditis

Sarcoidosis, Cardiac

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Exosome Analysis

Study Details

Brief summary:

The purpose of this study is to develop a prospective cohort of patients with and without cardiac sarcoidosis as well as active and inactive disease to develop a prospective biobank from which exosome analysis of peripheral blood will derive unique biomarkers of disease activity in cardiac sarcoidosis.

Conditions

Cardiac Sarcoidosis

Sarcoidosis of the Heart

Sarcoidosis With Myocarditis

Sarcoidosis, Cardiac

Study ID

NCT07604220

Start date

Jul 13, 2026

Status verified date

Aug, 2026

Completion date

Jul, 2028

Anticipated

Primary completion date

Jul, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria

  • Adults ≥18 years.
  • Patients referred to the Cardiac Sarcoid Clinic with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.
  • Undergoing FDG-PET as part of standard care.
  • Ability to provide informed consent.

Exclusion Criteria

• Inability to provide informed consent.

Study Design

Enrollment

115 participants

Anticipated

Interventions and Outcome Measures

Arms

Cardiac Sarcoidosis Patients

Patients with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.

Interventions

Exosome Analysis

Blood Samples will undergo exosome profiling using mass spectrometry and/or other discovery-based approaches

Primary outcome measure

  • Number of successful biomarker validations [ Time Frame: Baseline ]

Central Contacts and Locations

Central contacts

Anna Pick

507-255-0630pick.anna@mayo.edu

Locations

Mayo Clinic in Rochester

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Anna Pick

507-255-0630pick.anna@mayo.edu

Andrew Rosenbaum, MD

(507) 284-0783Rosenbaum.Andrew@mayo.edu

Principal Investigator:

Andrew Rosenbaum, MD

More Information

Sponsor

Mayo Clinic

Last update posted

Aug 17, 2026

Last verified

Aug, 2026

Keywords

  • cardiac sarcoidosis
  • FDG-PET
  • disease activity
  • proteomics

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-09. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-08-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.